- Home
- BGI vs ENLV Comparison
BGI vs ENLV Comparison
Compare BGI & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGI | ENLV |
|---|---|---|
| Founded | 1879 | 2005 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7M | 26.6M |
| IPO Year | 2005 | 1995 |
Fundamental Metrics
Financial Performance| Metric | BGI | ENLV |
|---|---|---|
| Price | $1.04 | $0.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 49.4K | ★ 488.4K |
| Earning Date | 12-05-2025 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $136,846,182.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.45 | N/A |
| 52 Week Low | $0.56 | $0.66 |
| 52 Week High | $2.03 | $2.10 |
Technical Indicators
Market Signals| Indicator | BGI | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 60.70 | 55.80 |
| Support Level | $0.85 | $0.85 |
| Resistance Level | $1.12 | $1.03 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 69.98 | 75.35 |
Price Performance
Historical ComparisonAbout BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.